Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 4/28/14  and contains information from public web pages and contributions from the ZoomInfo community.

Mr. Michael L. Kranda

Wrong Michael L. Kranda?

Chief Executive Officer

Local Address: Seattle, Washington, United States
Company Description: BEAT BioTherapeutics Corp. (BEATBio) is developing BB-R12, a novel biological therapy with the potential to revolutionize the treatment of heart failure. Heart...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • MBA
  • BA , finance
    University of Washington
171 Total References
Web References
Mr. Kranda, a member of our ...
www.sec.gov, 28 April 2014 [cached]
Mr. Kranda, a member of our Board, is a consultant to Vulcan Capital Venture Capital I LLC.
...
Mr. Kranda does not have voting or investment power over the shares held by Vulcan Ventures Incorporated and its affiliates, and disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
...
Mr. Kranda, a member of our Board, is a consultant to Vulcan Capital Venture Capital I LLC.
...
Mr. Kranda does not have voting or investment power over the shares held by Vulcan Ventures Incorporated and its affiliates, and disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
...
Mr. Kranda, a member of our Board, is a consultant to Vulcan Capital Venture Capital I LLC.
...
Mr. Kranda does not have voting or investment power over the shares held by Vulcan Ventures Incorporated and its affiliates, and disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
...
Mr. Kranda, a member of our Board, is a consultant to Vulcan Capital Venture Capital I LLC.
...
Mr. Kranda does not have voting or investment power over the shares held by Vulcan Ventures Incorporated and its affiliates, and disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
...
Michael Kranda(8)
...
Mr. Kranda, a member of our Board, is a consultant to Vulcan Capital Venture Capital I LLC.
...
Mr. Kranda does not have voting or investment power over the shares held by Vulcan Ventures Incorporated and its affiliates and disclaims beneficial ownership of such shares except to the extent of any beneficial ownership therein.
...
Michael Kranda Audit Committee
...
Mr. Kranda has served as a member of our Board since December 2003. Since September 2006, Mr. Kranda has served as a consultant to Vulcan Capital, the private investment group of Vulcan Inc., and Mr. Kranda served as Managing Director of biotechnology venture investments at Vulcan Capital from September 2003 to September 2006. From July 1996 to July 2002, Mr. Kranda served as Chief Executive Officer at Oxford GlycoSciences, a biotechnology company. Prior to joining Oxford GlycoSciences, Mr. Kranda was President and Chief Operating Officer at Immunex Corporation (now Amgen), a biopharmaceutical company.
...
Mr. Kranda currently serves as Chief Executive Officer and a director of BEAT BioTherapeutics Corporation, a gene therapy company. Mr. Kranda received a B.A. and an M.B.A from the University of Washington School of Business. We believe that Mr. Kranda is qualified to serve on our Board because of his many years of service as one of our directors, his extensive experience in the life sciences industry and his service on the boards of directors of other life sciences companies.
Michael Kranda, MBA - Chief ...
beatbiotherapeutics.com, 24 April 2014 [cached]
Michael Kranda, MBA - Chief Executive Officer - Mr. Kranda has over 25 years of biotech operating, finance and corporate development experience. Most recently Mr. Kranda was CEO of Vaccinogen, a cancer vaccine company. Mr. Kranda served as Managing Director of Vulcan Capital for several years, where he led all aspects of their Life Sciences investment efforts. Mr. Kranda was also the CEO of Oxford GlycoSciences, a pioneer in proteomic based drug and diagnostic product development.
...
Mr. Kranda started his biotech career at Immunex Corporation where he served as President, COO and Director and is currently a Director for PTC Therapeutics, Inc. (NASDAQ: PTCT).
...
Michael Kranda - Chief Executive Officer.
PTC Therapeutics: Michael Kranda
www.ptcbio.com, 5 Oct 2012 [cached]
Home > About Us > Leadership > Board of Directors > Michael Kranda Email Page Print SHARE THIS PAGE:
...
Michael Kranda
...
Michael Kranda
Vulcan Ventures, Inc.
Michael Kranda has been a member of PTC's board of directors since December 2003. Mr. Kranda is currently CEO, President and director of Anesiva, a publically traded biotech company in South San Francisco, CA. Prior to joining Anesiva, Mr. Kranda led life science venture investments as managing director for Vulcan Capital, and continues to serve as a consultant. From July 1996 to July 2002, Mr. Kranda served as Chief Executive Officer at Oxford GlycoSciences, a publically traded biotechnology company headquartered in London. Prior to joining Oxford GlycoSciences, Mr. Kranda was President and Chief Operating Officer at Immunex Corporation (now Amgen).
...
Mr. Kranda received his B.A. and M.B.A from University of Washington School of Business.
Orthopedic's Blog | tBlog.com
orthopedic.tblog.com, 1 Jan 2008 [cached]
"We believe Adlea holds promise for treating pain associated with a number of orthopedic surgical indications, and may reduce the need for other pain treatments such as opioids," said Michael L. Kranda, Anesiva's president and chief executive officer.
Anesiva Names Michael L. ...
www.pressrelated.com, 1 Feb 2012 [cached]
Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors Anesiva Names Michael L. Kranda as President, Chief Executiv | Press Release Press Related Press Releases
...
Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
...
Inc. (Nasdaq: ANSV) today announced the appointment of Michael L. Kranda as president, chief executive officer and a member of the company's board of directors, effective June 16, 2008. Mr. Kranda succeeds John P. McLaughlin,
...
"Michael is the ideal person to lead Anesiva as it transitions from a drug
...
Mr. Kranda is a seasoned biopharmaceutical executive who brings two decades of commercial operating and corporate development experience to Anesiva. Most recently, he was Managing Director for biotechnology and life science investments at Vulcan, Inc. where he played an active role in the product, business development and financing activities of multiple portfolio companies.
...
said Mr. Kranda. "I look forward to working with the talented employees of Anesiva to achieve these goals and build long-term value for stockholders."
"The members of the Anesiva board welcome Michael and thank John for his
...
Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO
Other People with the name "Kranda":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304